Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: A pediatric oncology phase II study
Autore:
Hurwitz, CA; Strauss, LC; Kepner, J; Kretschmar, C; Harris, MB; Friedman, H; Kun, L; Kadota, R;
Indirizzi:
Maine Childrens Canc Program, Scarborough, ME 04074 USA Maine Childrens Canc Program Scarborough ME USA 04074 rough, ME 04074 USA Maine Med Ctr, Barbara Rush Childrens Hosp, Portland, ME 04102 USA Maine Med Ctr Portland ME USA 04102 hildrens Hosp, Portland, ME 04102 USA Northwestern Univ, Sch Med, Chicago, IL USA Northwestern Univ Chicago IL USA hwestern Univ, Sch Med, Chicago, IL USA Childrens Mem Hosp, Chicago, IL 60614 USA Childrens Mem Hosp Chicago IL USA 60614 s Mem Hosp, Chicago, IL 60614 USA Pediat Oncol Grp Stat Off, Gainesville, FL USA Pediat Oncol Grp Stat Off Gainesville FL USA at Off, Gainesville, FL USA Boston Floating Hosp, Boston, MA USA Boston Floating Hosp Boston MA USABoston Floating Hosp, Boston, MA USA Hackensack Univ, Med Ctr, Hackensack, NJ USA Hackensack Univ Hackensack NJ USA sack Univ, Med Ctr, Hackensack, NJ USA UMDNJ, New Jersey Med Sch, Hackensack, NJ USA UMDNJ Hackensack NJ USAUMDNJ, New Jersey Med Sch, Hackensack, NJ USA Duke Univ, Med Ctr, Durham, NC USA Duke Univ Durham NC USADuke Univ, Med Ctr, Durham, NC USA St Jude Childrens Res Hosp, Memphis, TN 38105 USA St Jude Childrens Res Hosp Memphis TN USA 38105 sp, Memphis, TN 38105 USA Childrens Hosp San Diego, San Diego, CA USA Childrens Hosp San Diego San Diego CA USA p San Diego, San Diego, CA USA
Titolo Testata:
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
fascicolo: 5, volume: 23, anno: 2001,
pagine: 277 - 281
SICI:
1077-4114(200106/07)23:5<277:PFTTOP>2.0.ZU;2-O
Fonte:
ISI
Lingua:
ENG
Soggetto:
SALVAGE CHEMOTHERAPY; MALIGNANT GLIOMA; IN-VITRO; TAXOL; CHILDREN; CANCER; TRIAL; INFUSION; GROWTH; CELLS;
Keywords:
pediatrics; paclitaxel; phase II; brain tumor;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
32
Recensione:
Indirizzi per estratti:
Indirizzo: Hurwitz, CA Maine Childrens Canc Program, 100 US Route 1,Unit 107, Scarborough, ME 04074 USA Maine Childrens Canc Program 100 US Route 1,Unit 107 Scarborough ME USA 04074
Citazione:
C.A. Hurwitz et al., "Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: A pediatric oncology phase II study", J PED H ONC, 23(5), 2001, pp. 277-281

Abstract

Purpose: To assess the efficacy and define the toxicity of paclitaxel given at 3 dosage of 350 mg/m(2) every 3 weeks as a 24-hour continuous infusionto children with recurrent or progressive primary brain tumors. Patients and Methods: Seventy-three eligible patients, ages 3 months to 19years, with progressive or recurrent primary brain tumors were treated according to a Pediatric Oncology Group (POG) phase II protocol with paclitaxel (POG 9330). Tumor histologic strata included: astrocytoma (n = 4), malignant glioma (n = 13), medulloblastoma (n = 16), brain stem glioma (n = 15). ependymoma (n = 13), and miscellaneous histologies (n = 12). All patients had previous histologic confirmation of a primary intracranial or spinal cord tumor with magnetic resonance imaging or computed tomography documentation of unequivocally measurable progressive or recurrent disease. All patients had received previous therapy including surgery, radiation therapy, and/or chemotherapy, but no patient had been previously treated on more than onephase II trial. Paclitaxel was administered as a 24-hour intravenous infusion at a dosage of 350 mg/m(2) every 3 weeks. Neurologic and neuroradiologic reevaluations were performed after every second course. Patients were allowed to continue therapy for a total of 18 cycles in the absence of progressive disease or unacceptable toxicity. Results: Seventy-five patients were enrolled onto the FOG 9330 protocol; two ineligible patients were removed from the study before receiving any therapy. Of the 73 eligible patients, 72 were evaluable for toxicity and 70 were either fully or partially evaluable for disease response. There was one complete response and three partial responses (5.7%). Twenty patients had stable disease for more than 2 months. Toxicities included mild nausea, central nervous system toxicity, myelosuppression, and febrile neutropenia, including one septic death. One grade 2 and two grade 3 allergic reactions occurred. No cardiac toxicities or arthralgias were reported. Conclusion: Paclitaxel is well tolerated in children with recurrent or progressive brain tumors sit this dosage and schedule and may result in short-term disease stabilization in this: patient population. The lack of a significant number of patients with measurable: disease regression, however, precludes it from being identified as an active agent when administered as a single agent by 24-hour continuous infusion.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/09/20 alle ore 00:33:47